Immunocore Closes $312.1 Million Aggregate Financing, Makes Public Debut

London – February 23, 2021 – Cooley advised late-stage biotechnology company Immunocore on its $312.1 million aggregate financing, which consisted of a $297.1 million initial public offering of 11,426,280 American Depository Shares, including the full exercise of the underwriters’ option to purchase additional ADSs, and a $15 million concurrent private placement with the Bill & Melinda Gates Foundation. Partners Divakar Gupta, Claire Keast-Butler, Nicola Maguire and Eric Blanchard led the team advising Immunocore.

Goldman Sachs, J.P. Morgan Securities and Jefferies acted as joint book-running managers for the offering.

Immunocore, based in Oxfordshire, England with offices in Conshohocken, Pennsylvania, and Rockville, Maryland, is pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune. The company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Its ADSs now trade on the Nasdaq Global Select Market under the symbol “IMCR.”

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.